NAS 181

Drug Profile

NAS 181

Latest Information Update: 23 Jan 2007

Price : $50

At a glance

  • Originator Astra Arcus USA
  • Class Antidepressants; Benzopyrans; Morpholines; Small molecules
  • Mechanism of Action Serotonin 1B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 23 Jan 2007 Discontinued - Preclinical for Depression in Sweden (unspecified route)
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 09 Dec 1998 Preclinical development for Depression in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top